Compare · LLY vs PCRX
LLY vs PCRX
Side-by-side comparison of Eli Lilly and Company (LLY) and Pacira BioSciences Inc. (PCRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and PCRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.18T, about 813.6x PCRX ($1.45B).
- LLY has been more active in the news (25 items in the past 4 weeks vs 7 for PCRX).
- Both have 25 recent analyst ratings on file.
- Company
- Eli Lilly and Company
- Pacira BioSciences Inc.
- Price
- -
- -
- Market cap
- $1.18T
- $1.45B
- 1M return
- +9.10%
- -
- 1Y return
- +56.51%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2011
- News (4w)
- 25
- 7
- Recent ratings
- 25
- 25
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Pacira BioSciences Inc.
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Parsippany, New Jersey.
Latest LLY
- Lilly confirms date and conference call for third-quarter 2026 financial results announcement
- New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year
- Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver Slide
- Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
- Record Highs Beckon for Big Caps as Small Caps Lag and Deal Flow Builds
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity
- SEC Form 3 filed by Eli Lilly and Company
- Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions
- Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
- Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
Latest PCRX
- SEC Form 4 filed by Pacira BioSciences Inc.
- SEC Form SC14D9C filed by Pacira BioSciences Inc.
- SEC Form 8-K filed by Pacira BioSciences Inc.
- Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
- Pacira BioSciences and Caregiver Action Network Announce New Survey on Gaps in Preparing Families for Postsurgical Recovery at Home
- Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom
- Oppenheimer initiated coverage on Pacira BioSciences with a new price target
- Leerink Partners initiated coverage on Pacira BioSciences with a new price target
- Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Chief Medical Officer Slonin Jonathan sold $70,619 worth of shares (3,040 units at $23.23) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 216,384 units (SEC Form 4)